After nearly four decades of research, a safe and effective HIV-1 vaccine remains elusive.
There are many reasons why the development of a potent and durable HIV-1 vaccine is …

The recombination between immunoglobulin (IG) gene segments determines an individual's
naïve antibody repertoire and, consequently,(auto) antigen recognition. Emerging evidence …

Antibody responses are characterized by increasing affinity and diversity over time. Affinity
maturation occurs in germinal centers by a mechanism that involves repeated cycles of …

HIV-1 broadly neutralizing antibodies (bNAbs) are able to suppress viremia and prevent
infection. Their induction by vaccination is therefore a major goal. However, in contrast to …

A key aspect of successful viral vaccine design is the elicitation of neutralizing antibodies
targeting viral attachment and fusion glycoproteins that embellish viral particles. This …

Anti-HIV broadly neutralizing antibodies (bNAbs) offer a novel approach to treating,
preventing, or curing HIV. Pre-clinical models and clinical trials involving the passive transfer …

Deep learning has led to incredible breakthroughs in areas of research, from self-driving
vehicles to solutions, to formal mathematical proofs. In the biomedical sciences, however …

Human immunodeficiency virus type 1 (HIV-1)-neutralizing antibodies (nAbs) that prevent
infection are the main goal of HIV vaccine discovery. But as no nAb-eliciting vaccines are yet …

HIV-1 broadly neutralizing antibodies (bNAbs) can decrease viremia but are usually unable
to counteract autologous viruses escaping the antibody pressure. Nonetheless, bNAbs may …

The HIV-1 fusion peptide (FP) represents a promising vaccine target, but global FP
sequence diversity among circulating strains has limited anti-FP antibodies to~ 60 …